FindTrial
Sign In

FancoMob: Pilote study for a combined treatment helping to collect stem cells in patient suffering Fanconi anemia

NA - EUROFANCOLEN

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-005264-14-FR
Enrollment
Unknown
Registered
2015-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fanconi Anemia MedDRA version: 18.1 Level: LLT Classification code 10055206 Term: Fanconi's anemia System Organ Class: 100000004850

Interventions

Trade Name: Zarzio Product Name: Zarzio Pharmaceutical Form: Solution for injection INN or Proposed INN: filgrastim Other descriptive name: G-CSF Concentration unit: IU/ml international unit(s)/millil

Sponsors

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NA Are the trial subjects under 18? yes Number of subjects for this age range: 8 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Main Objective: NA;Secondary Objective: ;Primary end point(s): NA;Timepoint(s) of evaluation of this end point: after visit of each patient—

Secondary

MeasureTime frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: up to 30 days after last injection—

Countries

France

Contacts

Public ContactProject manager

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

didier.bouton@aphp.fr33144.84.17.44

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 20, 2026